The Phase I study is a randomized, double-blind and placebo-controlled single ascending dose study to evaluate the safety and tolerability as well as the pharmacokinetic profile of ACR343 after oral administration. The study will be performed in Sweden.
In preclinical studies, ACR343 has been able to stabilise motor function in a variety of models for CNS disorders. In a specific model for Parkinson’s disease, ACR343 reduces involuntary movements resulting from treatment with L-Dopa without compromising its anti-parkinsonian effects. NeuroSearch holds all rights to ACR343.
Flemming Pedersen, CEO of NeuroSearch, said: “ACR343 is the third drug candidate to be brought into the clinic as a result of our activities in the promising field of dopaminergic stabilizers, where NeuroSearch has a leading position.”